Abstracts tagged "Lupus and biomarkers"

Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…
Abstract Number: 1702 • 2018 ACR/ARHP Annual Meeting
Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease
Emily Liang¹, Mihaela Taylor² and Maureen A. McMahon³, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The AVISE Connective Tissue Disease test is a newly approved, commercially available test that combines autoantibody and biomarker levels to help diagnose systemic lupus…
Abstract Number: 2344 • 2017 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products As Markers of Disease Flares in Childhood Onset Systemic Lupus Erythematosus
Yevgeniya Gartshteyn¹, Joyce Hui-Yuen², Miya Okado¹, Teja Kapoor¹, Thierry Dervieux³ and Anca Askanase⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Pediatric Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³3Exagen Diagnostics, Albuquerque, CA, ⁴Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Cell-bound complement activation products, CB-CAPs (C4d deposition on erythrocytes [EC4d], B lymphocytes [BC4d], reticulocytes [RC4d], platelets [PC4d], and C3d deposition on reticulocytes [RC3d]) are…
Abstract Number: 756 • 2015 ACR/ARHP Annual Meeting
Axl, Ferritin, IGFBP2 and TNFR2 As Biomarkers in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Huihua Ding², Marwa Kharboutli³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: To evaluate the performance of 4 novel serum protein markers for detecting concurrent disease activity in systemic lupus erythematosus (SLE). Methods: Consecutive patients who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].